Mylonakis Eleftherios, Ziakas Panayiotis D
Charles C. J. Carpenter Professor of Infectious Diseases at Brown University in Providence, Rhode Island.
Author of more than 100 peer-reviewed publications in the fields of infections, hematology/oncology, autoimmunity, and epidemiology.
AMA J Ethics. 2021 Aug 1;23(8):E631-638. doi: 10.1001/amajethics.2021.631.
Nosocomial infections are public health threats with often grave human costs. Because implementing screening and best outbreak response practices is costly for health care organizations, allocating resources for interventions requires consensus among stakeholders with a plurality of perspectives about how to weigh prospective interventions' risks and benefits. Economic analysis can facilitate decision making but is relatively new in nosocomial infection prevention and control. This article describes features of and reasons for economic analysis in this specific area and focuses on emerging challenges in antimicrobial stewardship.
医院感染是对公共卫生的威胁,往往会带来巨大的人力成本。由于实施筛查和最佳疫情应对措施对医疗机构来说成本高昂,因此为干预措施分配资源需要利益相关者达成共识,而他们对于如何权衡前瞻性干预措施的风险和益处有着多种不同的观点。经济分析有助于决策制定,但在医院感染预防与控制领域相对较新。本文描述了该特定领域经济分析的特点和原因,并重点关注抗菌药物管理方面新出现的挑战。